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Abstract 
Introduction. The analysis of the epidemiological data on cancer is an important tool to 
control and evaluate the outcomes of primary and secondary prevention, the effective-
ness of health care and, in general, all cancer control activities. 
Materials and methods. The aim of the this paper is to analyze the cancer mortality 
in the Umbria region from 1978 to 2009 and incidence from 1994-2008. Sex and site-
specific trends for standardized rates were analyzed by “joinpoint regression”, using the 
surveillance epidemiology and end results (SEER) software. 
Results. Applying the jointpoint analyses by sex and cancer site, to incidence spanning 
from 1994 to 2008 and mortality from 1978 to 2009 for all sites, both in males and 
females, a significant joinpoint for mortality was found; moreover the trend shape was 
similar and the joinpoint years were very close. In males standardized rate significantly 
increased up to 1989 by 1.23% per year and significantly decreased thereafter by -1.31%; 
among females the mortality rate increased in average of 0.78% (not significant) per year 
till 1988 and afterward significantly decreased by -0.92% per year. Incidence rate showed 
different trends among sexes. In males was practically constant over the period studied 
(not significant increase 0.14% per year), in females significantly increased by 1.49% per 
year up to 2001 and afterward slowly decreased (-0.71% n.s. estimated annual percent 
change − EAPC).
Conclusions. For all sites combined trends for mortality decreased since late ’80s, both 
in males and females; such behaviour is in line with national and European Union data. 
This work shows that, even compared to health systems that invest more resources, the 
Umbria public health system achieved good health outcomes. 
INTRODUCTION
The analysis of the epidemiological data on cancer is 
an important tool to control and evaluate the outcomes 
of primary and secondary prevention, the effectiveness 
of health care and, in general all cancer control activi-
ties [1-4]. 
Trends in cancer incidence and mortality in Europe 
are generally going in the right direction in the more 
wealthy countries starting from the North/North-West 
countries, showing that the cancer prevention and man-
agement activities in Europe and in particular in the 
European Union, is giving some kind of results [5].
Also in Italy, cancer incidence and mortality show the 
same trends as the rest of Western Europe. Mortality 
decreased for the most cancer sites, the incidence in-
creased only for those diagnosed by population screen-
ing (e.g. colorectal and, in minor extent, female breast 
cancers) or individual one (e.g. thyroid, melanoma) and 
in females for lung cancer and Hodgkin lymphoma [6].
In the Umbria region of Italy, several studies have 
been carried-out on geographic distribution and tem-
poral trend of cancer incidence and mortality [2, 7]. 
Umbria is a small region in the centre of Italy (900 790 
inhabitants). Regional health structures, including two 
main oncology centres (Perugia and Terni), are easy to 
reach by all residents. Regional population screening in-
terventions were introduced in 1997 for breast cancer, 
in 1999 for cervical cancer and in 2006 for colorectal 
cancer [8, 9]. Several years before the start of popula-
tion screening the regional health system was offering 
free pap smear test for cervix cancer. Since the late ’80s 
opportunistic screening activities for skin melanoma 
and prostate cancer have became more and more popu-
lar. In particular for prostate cancer, in the late eighties 
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digital rectal examination first and prostate specific an-
tigen (PSA) test later began to spread [10].
A regional cancer registry, the Umbrian Population 
Cancer Registry (RTUP), was established in the early 
’90, consequently data on incidence, prevalence and 
survival are available for the period 1994-2009. The reg-
istry also collects regional mortality data from munici-
pal offices and death certificates, and publishes official 
yearly general mortality statistics [11].
The aim of this paper is to analyze the cancer mor-
tality in the Umbria region, from 1978 to 2009 and 
incidence, from 1994-2008. Possible explanations of 
observed trends will be proposed with a particular at-
tention to the period 1994-2008. 
MATERIALS AND METHODS
Mortality data was supplied by the National Institute 
of Statistics (ISTAT) until 1993, while, for the following 
1994-2009 period, by the Regional Nominative Causes 
of Death Registry (ReNCaM), based on the Popula-
tion Register Offices of the Umbrian municipalities 
linked with the archives of death certificates collected 
by the Local Health Districts and afterwards used by 
ISTAT. No major or systematic difference seems to 
exist comparing ISTAT and ReNCaM based mortal-
ity data and, since ReNCaM data are updated earlier 
than ISTAT mortality data, they allow the inclusion of 
more recent years in the analysis [12]. Incidence data 
derived from RTUP and are referred to the 1994-2008 
period. Causes were classified according to the X Inter-
national Classification of Diseases (version 7). Cancer 
sites examined are listed in Table 1. For each site the 
age-adjusted rates (AADR) have been calculated. Sex 
and site-specific trends for standardized rates were ana-
lyzed by “joinpoint regression”, using the Surveillance 
Epidemiology and End Results (SEER) software [13]. 
The European population was used as standard for age 
standard adjustment in the joinpoint analyses. The grid 
search method allows the detection of segments best 
describing data. The maximum number of joinpoints 
allowed for each analysis were three for incidence and 
four for mortality. The expected annual percent changes 
(EAPCs) are reported to describe linear trends by pe-
riod. In this way it is possible to identify for each period 
a distinct linear, or log-linear trends of rates separated 
by joinpoints. Within different joint points the EAPC 
was labelled as statistically significant when its 95% 
confidence interval did not include zero. The method 
follows the principle of minimization of the weighted 
sum of squared errors and the choice of the number of 
joinpoints is on the basis of permutation tests [14].
Neoplasm of haematopoietic tissue, and other unre-
ported sites, were disregarded because of the very high 
variability of rates, over the studied period, in relation 
to the low number of cases. The definition of head 
and neck cancer is not standard; we included mouth, 
tongue, and pharynx sites (C01-C06, C10-C13) and 
reported separately larynx cancer trend among males. 
Uterus was considered as a total and undefined uterus 
(C53-C55) both for mortality and incidence, since the 
inaccuracy of death certifications (leading to the as-
signment of C55 code) was not constant but decreas-
ing over the study period. A separate analysis of cervix 
(C53) and uterus (C54) was possible only for incidence. 
RESULTS
The estimated annual percent change (EAPC) by 
jointpoint analyses by sex and cancer site, applied to 
incidence spanning from 1994 to 2008 and mortality 
from 1978 to 2009 are reported in Table 1.
For all sites, both in males and females, a significant 
joinpoint for mortality was found (Figure 1); moreover 
the trend shape was similar and the joinpoint years were 
very close. In males standardized rate significantly in-
creased up to 1989 by 1.23% per year and significantly 
decreased thereafter by -1.31%; among females the 
mortality rate increased in average of 0.78%, not signifi-
cant (n.s.), per year till 1988 and afterward significantly 
decreased by-0.92% per year. Incidence rate showed 
different trends among sexes. In males was practically 
constant over the period studied (n.s. increase 0.14% 
per year), in females significantly increased by 1.49% 
per year up to 2001 and afterward slowly decreased 
(-0.71% EAPC, n.s.).
Figure 2 reports, only for males, the temporal trends 
of head and neck, oesophagus, larynx and prostate can-
cer. The first three cancer sites presented a similar trend, 
without joinpoints. The rates decreased significantly 
both in mortality and incidence respectively by -2.36% 
and -2.92% in head and neck cancer, -2.07% and -6.05% 
per year in esophagus cancer and -3.17% and -2.93% per 
year in larynx cancer. Prostate cancer mortality trend is 
the only one, among these, showing a significant trend 
with two joinpoints: the rates decreased up to 1989 
(-1.99%), then increased up to 1998 (2.66%) and finally 
decreased (-4.09% EAPC). Incidence showed a con-
stant and significant increase of 3.50% per year.
Gastric cancer showed different mortality trends by 
gender. In males it was slightly increasing up to 1985 
(1.42% n.s.) and significantly decreasing after this year 
(-3.43% EAPC). It was constantly decreasing among 
females over the study period and the trend showed 
a joinpoint in 1994 where the EAPC switched from 
-1.80% to -4.06%. Incidence constantly decreased in 
both sexes over the studied period (-3.66% in males and 
-3.73% in females). 
Colon cancer in males showed a significant increase in 
mortality rate (2.65%) up to 1997 and afterward slightly 
decreasing (-0.31% n.s.). The incidence significantly in-
creased (1.85%) in the period under investigation. In fe-
males both trends in incidence and mortality increased 
respectively of 0.87% (n.s.) and 0.65%. On the contrary, 
rectum cancer showed a significant decrease in mortal-
ity (-2.25% in males and -2.46% in females); no signifi-
cant trends for incidence were detected for both females 
and males (respectively -1.29% and 0.26% n.s.).
Liver and pancreas showed heterogeneous trends. 
Mortality from hepatic cancer in males significantly in-
creased up to 1990 (4.74%) and afterward decreased 
(-1.63% per year), in females it decreased over all stud-
ied period (-1.77%); incidence for both genders was 
slightly decreasing (-1.04% in males and -1.11% in fe-
males, n.s. EAPC). Pancreatic cancer mortality and 
incidence increased both in males and in females but 
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Table 1
Joinpoint analysis by sex and selected cancer site in the Umbria region (Italy)*
Site ICD10 Mortality Confidence interval Incidence Confidence interval
Sex Period EAPC1 Lower Upper Period EAPC Lower Upper
All sites C00-C97 M 1978-1989 1.23* 0.41 2.04 1994-2008 0.14 -0.24 0.53
M 1989-2009 -1.31* -1.60 -1.02
F 1978-1988 0.78 -0.11 1.68 1994-2001 1.49* 0.52 2.46
F 1988-2009 -0.92* -1.19 -0.65 2001-2008 -0.71 -1.61 0.19
Head and neck 
C01-C06, C10-C13
M 1978-2009 -2.36* -3.20 -1.51 1994-2008 -2.92* -4.46 -1.36
Esophagus C15 M 1978-2009 -2.07* -3.04 -1.08 1994-2008 -6.05* -8.93 -3.07
Stomach C16 M 1978-1985 1.42 -1.78 4.73 1994-2008 -3.66* -4.58 -2.73
M 1985-2009 -3.43* -3.94 -2.92
F 1978-1994 -1.80* -2.61 -0.98 1994-2008 -3.73* -5.06 -2.38
F 1994-2009 -4.06* -5.03 -3.09
Colon C18-C19 M 1978-1997 2.65* 1.80 3.51 1994-2008 1.85* 0.56 3.15
M 1997-2009 -0.31 -1.55 0.95
F 1978-2009 0.65* 0.04 1.25 1994-2008 0.87 -0.32 2.08
Rectum C20-C21 M 1978-2009 -2.25* -2.91 -1.59 1994-2008 0.26 -1.40 1.94
F 1978-2009 -2.46* -3.21 -1.70 1994-2008 -1.29 -2.83 0.28
Liver C22 M 1978-1990 4.74* 1.11 8.50 1994-2008 -1.04 -2.37 0.31
M 1990-2009 -1.63* -2.99 -0.26
F 1978-2009 -1.77* -2.38 -1.16 1994-2008 -1.11 -3.81 1.67
Pancreas C25 M 1978-2009 0.38 -0.26 1.02 1994-2008 1.16 -0.58 2.94
F 1978-2009 1.10* 0.44 1.77 1994-2008 1.57* 0.50 2.66
Larynx C32 M 1978-2009 -3.17* -3.73 -2.61 1994-2008 -2.93* -4.86 -0.96
Lung C33-C34 M 1978-1987 3.88* 1.71 6.10 1994-2008 -1.78* -2.16 -1.41
M 1987-2009 -1.27* -1.74 -0.79
F 1978-2009 2.49* 1.97 3.00 1994-2008 2.48* 0.94 3.05
Skin melanoma C43 M 1978-2009 2.00* 0.44 3.59 1994-2008 2.59 -0.39 5.65
F 1978-2009 3.04* 1.65 4.45 1994-2008 1.76 -1.19 4.80
Breast C50 F 1978-1994 0.90 -0.21 2.03 1994-2001 3.62* 1.43 5.85
F 1994-2009 -1.60* -2.75 -0.44 2001-2008 -1.79 -3.7 0.17
Uterus C53-C55 F 1978-2006 -3.13* -3.81 -2.46 1994-2008 -1.10 -2.45 0.26
F 2006-2009 14.16 -7.79 41.34
Cervix uteri C53 F - - - - 1994-2008 -1.84 -4.20 0.57
Body of uterus C54 F - - - - 1994-2008 -0.69 -1.96 0.59
Ovary C56 F 1978-1985 11.18* 1.68 21.56 1994-2008 -2.06* -3.69 -0.41
F 1985-2009 -0.50 -1.58 0.59
Prostate C61 M 1978-1989 -1.99* -3.83 -0.12 1994-2008 3.50* 2.22 4.78
M 1989-1998 2.66* 0.00 5.39
M 1998-2009 -4.09* -5.51 -2.65
Urinary bladder C67 M 1978-2009 -0.49 -1.08 0.11 1994-2000 0.77 -4.22 6.03
M 2000-2008 -7.24* -10.5 -3.85
F 1978-2009 -0.81* -1.16 -0.02 1994-2008 -3.83* -5.09 -2.55
Brain C71 M 1978-2009 1.43* 0.74 2.12 1994-2008 -1.24 -3.42 0.99
F 1978-2009 1.00* 0.05 1.95 1994-2008 -2.72* -4.54 -0.86
Thyroid C73 M 1978-2009 1.07 -1.06 3.25 1994-2008 5.09* 1.80 8.50
F 1978-2009 -2.73* -4.18 -1.25 1994-1996 55.75 -16.11 189.17
F 1996-2008 3.65* 1.31 6.03
1EAPC: estimated annual percent change.
*Significant change (p < 0.05). Only significant joinpoints (p < 0.05) were retained in final models for each site.
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Figure 1 
Observed standardized rates per 100 000 inhabitants of incidence (diamond marker) and mortality (triangle marker) and “best” 
joinpoint model estimates (solid line) for all sire cancers.
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Figure 2
Observed standardized rates per 100 000 inhabitants of incidence (diamond marker) and mortality (triangle marker) and “best” 
joinpoint model estimates (solid line) for head and neck (C01-C06, C10-C13), esophagus (C15), larynx (C32) and prostate (C61) 
cancers.
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no significant in males (0.38% mortality and 1.16% in-
cidence EAPC) while in females increases were signifi-
cant (1.10% and 1.57% respectively).
Lung cancer mortality rates in males significantly 
increased (3.88%) up to 1987 and decreased after 
(-1.27%); the incidence for the overall period decreased 
significantly (-1.78%). In females, both mortality and 
incidence increased by 2.49% and 2.48% (significant 
EAPC) respectively.
The trends relative to skin melanoma were always in-
creasing, significantly in mortality (2.00% in males and 
3.04% in females) and not significantly in incidence 
(2.59% in males and 1.76% in females).
Trends in female breast cancer presented a joinpoint 
both in mortality and in incidence (Figure 3). Mortality 
increased (0.90% n.s.) up to 1994 and after significantly 
decreased (-1.60%); incidence significantly increased in 
rates (3.62%) up to 2001 and then decreased (-1.79% 
n.s.).
The rates relative to ovary cancer (Figure 3) present 
a significant increase trend up to 1985 (11.18%), while 
afterward the trend slowly decrease (-0.50% n.s.); the 
incidence decreased over the study period by -2.06% 
per year, statistically significant.
Brain cancer showed a steady and significant increase 
in mortality (1.43% in males and 1.00% in females), and 
decrease in incidence (-1.24% and -2.72% in two sexes 
respectively) significantly also in females.
The trends relative to cervix and body of uterus are 
described only for incidence; the relative decrease is not 
significant for both (cervix -1.84% and body -0.69%). The 
analysis for total uterus cancer confirmed for incidence a 
no significant decrease; on the contrary mortality trend 
was significantly decreasing up to 2006 (-3.13%), while 
the following increase (14.16%) is not significant.
Regressions relative to urinary bladder, brain and 
thyroid cancer are documented. For urinary bladder 
cancer, a joinpoint was detected only for incidence in 
males: it increased till year 2000 (0.77% n.s.) and then 
significantly decreased (-7.24% EAPC). For mortal-
ity no significant trends were detected (-0.49% EAPC 
n.s.). In females both mortality and incidence decreased 
significantly over the study period.
Mortality rate in male is quite constant (+1.07% n.s.) 
and decreased in females by -2.73% per year (statisti-
cally significant) for thyroid cancer. The trend analysis 
of this site is affected by the low number of cases: in-
cidence constantly increased for males (5.09%), for fe-
males increased up to 1996 (55.75% n.s., probably due 
to the low number of cases) and afterward increased 
significantly by 3.65% per year till the period considered. 
CONCLUSIONS
The present study shows for most cancer sites a re-
duction trend for mortality and incidence in the Um-
bria region. For all sites combined trends for mortality 
decreased since late ‘80s, both in males and females; 
such behaviour is in line with national and European 
Union data [3-5]. The global burden of cancer remains 
high in developed countries and is growing in those 
developing [15, 16]. This is due to an increase in the 
average expected life span and to a high prevalence of 
environmental and behavioural risk factors that in the 
past were present almost exclusively in western societ-
ies, such as air pollution, smoking, alcohol consump-
tion, high-fat diet and physical inactivity [15]. Approxi-
mately 30% of all deaths from cancer are attributable 
to tobacco smoking and unhealthy diets and physical 
inactivity [17]. 
During the period considered the Umbria region 
shows a decrease in incidence of upper aero digestive 
tract cancer [7]. This trend was also observed for mor-
tality rates, for the same cancer, among males and fe-
males. This favourable regional pattern is in line with 
the trends in the rest of Southern Europe [18]. In Italy, 
as in France and in Spain, the observed trends largely 
reflect two major changes in individual behaviours: the 
fall of tobacco smoking habit among males and the de-
cline in alcohol consumption [4, 19]. It was estimated 
that at least three quarters of oral cavity cancers are pre-
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Figure 3 
Observed standardized rates per 100 000 inhabitants of incidence (diamond marker) and mortality (triangle marker) and “best” 
joinpoint model estimates (solid line) for female breast (C50), and ovary (C56) cancers.
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ventable with the eradication of smoking and alcohol 
habit [20, 21]. The decrease of the above-mentioned 
risk factors does not fully justify the fall of esophageal 
cancer. This decline in incidence that occurred can also 
be explained by early detection of precancerous lesions 
and subsequent early treatment of the lesion; although 
the evidence is not yet sufficient. 
Historically the Umbrian region is a high risk area 
for gastric cancer [7]. The reason of this high incidence 
can find its explanation in the local dietary pattern 
[22]. In the period observed, incidence rates decreased 
in both sexes. Mortality trend is constantly decreas-
ing among Umbrian females, while in Umbrian males 
there’s a slight increase up to 1985 and a decrease after. 
The trends observed in the Umbrian region are quite 
similar to those observed in the rest of Italy [6]. The 
decrease in mortality rates in Umbria is closely linked 
to the reduction in the number of new cases and also 
to the implementation of the Umbrian oncology health 
care system [23]. Despite the favourable trends during 
the last decades, the gastric cancer still ranks fourth in 
Umbrian males and fifth for the females [24, 25]. The 
same of Italy where this cancer is the fifth in frequency 
in both sexes and the fourth leading cause of cancer 
death in males and the fifth in females [23].
The incidence rate of liver cancer in the Umbria re-
gion shows a moderate decreasing trend in both sexes. 
Downward trends in mortality were observed among 
females over all period and in males since 1990. For 
the same period in Italy no large incidence and mor-
tality changes were reported in liver cancer but rather 
a slight steady downward trend since the mid-nineties 
[6]. Across Europe, indeed, liver cancer shows a large 
heterogeneity with the presence of three main different 
risk geographical areas [26]. Incidence and mortality 
data on liver cancer in Umbria is difficult to interpret 
and subject to large uncertainties and errors [27]. Fur-
thermore, improvements in liver cirrhosis surveillance 
led to an increase in liver cancer diagnosis and in coun-
tries where mortality for cirrhosis is relatively frequent, 
the exchange of cirrhosis with liver cancer on death 
certification, even if in a few cases, may have an im-
portant effect [27]. Even with these limitations, we can 
state that the downward trend in Umbria is, at least in 
part, real. Indeed, declined prevalence of hepatotropic 
viruses infections and alcohol consumption may have 
contributed to the observed trend [28]. Regarding the 
different frequencies of liver cancer by gender, it is in 
line with the worldwide trend. 
Lung cancer among Umbrian females shows an in-
crease both in incidence and in mortality. The corre-
sponding incidence rates in Umbrian males decreases 
for the same period, constituting third cancer in fre-
quency [24]. The same trends are observed in the rest of 
Italy [6]. This is perfectly in line with the international 
data [29, 30]. Gender differences in rates of lung cancer 
observed in Umbria and in the rest of Italy are also due 
to different trends in the prevalence of smoking [31]. In 
the last decade most of the prevention activities carried 
out in Italy have been dedicated against smoking habit 
[32]. Lung cancer mortality trends are quite similar to 
incidence trends because the prognosis continues to be 
very poor [6]. Indeed the survival for patients with lung 
cancer is only three years in advanced stage cases [30]. 
In many studies a decreasing trend for breast cancer 
was observed since the beginning of the twenty-first cen-
tury for Italy as well as for many industrialized coun-
tries (e.g. USA 2001-2004 [33], Germany 2002-2005 
and France 2003-2006 [34-37]). Breast cancer trend 
for Umbria is consistent with these findings. Due to the 
poor diffusion of the hormone replace therapy (HRT) in 
Italy [37], the incidence trends in different age cohorts 
for invasive and intraductal breast cancer in the period 
1994-2008 have been studied. Different age cohorts 
were analyzed: 40-49, 50-69and 70-79 years old. The 
organized breast cancer screening started in 1998. The 
data underlines a significant increase of invasive cancer 
only in the screening cohort (50-69) till 2001. This result 
is consistent with the first organized screening program 
in 1997. Furthermore it can be assumed that the health 
promotion campaign induced a higher participation to 
breast opportunistic screening. The following decreasing 
trend maybe partially due to two consequences of the 
screening program: the saturation and the diagnostic 
anticipation. In effect the data shows for the same peri-
od an increase in the number of diagnosis of intraductal 
neoplasm. The increasing trends in the pre-screening 
cohort during the overall study period could be related 
to the implementation of the opportunistic screening. 
Moreover, in the over 70 cohort the trend of infiltrating 
neoplasm shows a slight decrease in rate (n.s.), which 
could be related to diagnostic anticipation. 
The mortality for rectal cancer is decreasing in both 
sexes while this is not true for colon carcinoma (only 
lightly decreasing since 1997 in males and steady in 
women). These results reinforce the need to promote 
screening activities that will allow not only to achieve 
the reduction of mortality, but also a strong improve-
ment of the quality of life. 
The trends in incidence and mortality for this cancer 
vary in the world and in the EU. This heterogeneity can 
be largely interpreted by analyzing the coverage and qual-
ity of screening, the changes in exposure to risk factors 
that are mainly related to sexual habits and persistent 
infection of human papilloma-virus [38]. Countries with 
organized screening programs in the last decades have 
witnessed a significant decrease in incidence and mor-
tality [38]. In Umbria the organized screening started 
in 1999 (although preceded by an opportunistic one). 
The incidence of cervical cancer shows a decrease trend, 
probably due to the program: about 85% of women aged 
25-64 years reported having a preventive Pap test (57% 
within an organized screening program, 28% as individual 
prevention). Such explanation is supported by the sharp 
increase in severe dysplasia, APC 6.75 (CI 4.98-8.55).
Incidence and mortality trends for prostate can-
cer in Umbria agree with Italian trends and Western 
countries. The decrease of mortality can deal with the 
improvements of the surgery and radio therapeutic 
treatments and to the role of opportunistic screening 
through PSA. PSA screening has spread spontaneously 
mainly to its simplicity [39].
Skin melanoma mortality trends in Umbria grow 
for the overall study period, incidence presents an 
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unstable trend. Such differences could be due to the 
low number of cases and also to the effects of informa-
tion campaigns. It is well known that eighty percent of 
melanoma is due to damages from ultraviolet on very 
sensible skin, particularly dangerous are episodic expo-
sure during the childhood [40]. Primary prevention of 
melanoma is therefore based on the use of protective 
measures [41]. Anyway some studies demonstrated 
that the only sunscreen use was even associated with in-
creased risk of cutaneous melanoma [42]. Screening for 
skin melanoma is based on a specialist visit. The evalu-
ation of a pilot project in Germany demonstrated that 
an organized population based skin cancer screening is 
useful to detect more cases of early stage melanomas. 
Comparing to the average melanoma mortality in Ger-
many a reduction of about 50% could be detected in the 
screened population [43]. These promising results sug-
gest that combining secondary prevention with primary 
prevention interventions could be effective to fight skin 
melanoma incidence and mortality. 
The analysis of trends for thyroid cancer could have 
been associated to the cancers which benefit of primary 
prevention interventions; this is because the risk factors 
are largely known and sometimes modifiable [42, 44]. 
Nevertheless the problem needs to be analyzed sepa-
rately because many authors highlighted for thyroid car-
cinoma the role of so-called “incidental screening”. In 
Europe as well as all over the world many studies have 
documented an increase in thyroid cancer incidence 
in the last two or three decades while for mortality the 
trend is stable [45]. For Italy the increasing trend for 
incidence was confirmed especially in women, while 
mortality for both genders was characterized by a no 
significant decrease [6]. Time trend in Umbria, even if 
affected by the poor number of cases, seems to be in 
line with the Italian epidemiologic frame; the only differ-
ence is the significant decrease in mortality for females. 
As already mentioned, many authors addressed the in-
creasing incidence to the improvement of the diagnostic 
techniques which could be a consequence of un oppor-
tunistic screening intervention. Particularly some stud-
ies stressed how the increase in thyroid cancer incidence 
affected only small nodules while other authors showed 
significant increases of differentiated thyroid cancers of 
all sizes formulating the hypothesis that other factors 
could have contributed to the incidence rate [46-48]. 
In the US Cancer Statistic report, 2011, the authors 
confirmed what already stressed in the 2008 report: 
“Cancer replaced heart disease as the leading cause of 
death among men and women aged younger than 85” 
[17]. The World Health Organization (WHO) estimates 
that about 40% of all cancer deaths can be prevented 
[49]. Starting from these last points it is important to 
assess trends of incidence and mortality cancer in rela-
tion to primary and secondary prevention interventions.
This works shows how a public health system funded 
with only 9.5% of GDP [50], with still some several in-
efficiencies (esp. insufficient standardized protocols) 
and low investment in primary prevention (less 1% of 
GDP) presents numbers much better than other coun-
tries ranking always in the first ten of WHO [51, 52]. 
The data reassures the public health experts from this 
point of view, considering also that the trends are com-
parable with other European countries with a global 
funding much higher as: The Netherlands, France and 
Germany [53]. 
Conflict of interest statement
None.
Received on 18 May 2014.
Accepted on 27 April 2015.
REFERENCES
1. Ito Y, Ioka A, Tanaka M, Nakayama T, Tsukuma H. 
Trends in cancer incidence and mortality in Osaka, Ja-
pan: Evaluation of cancer control activities. Cancer Sc 
2009;100:2390.
2. Stracci F, Canosa A, Minelli L, Petrinelli AM, Cassetti T, 
Romagnoli C, La Rosa F. Cancer mortality trends in the 
Umbria region of Italy 1978-2004: a joinpoint regression 
analysis. BMC Cancer 2007;2:10.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of 
cancer incidence and mortality in Europe in 2008. Eur J 
Cancer 2010;46(4):765-81. 
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, 
Coebergh JWW, Comber H, Forman D, Bray F. Cancer 
incidence and mortality patterns in Europe: Estimates for 
40 countries in 2012. Eur J Cancer 201;9(49):1374-403.
5. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens 
V, Siesling S, Coebergh JW. Recent trends of cancer in 
Europe: a combined approach of incidence, survival and 
mortality for 17 cancer sites since the 1990s. Eur J Cancer 
2008;44:1345.
6. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. 
European cancer mortality predictions for the year 2014. 
Ann Oncol 2014;25(8):1650-6.
7. Rossi S, Crocetti E, Capocaccia R, Gatta G, AIRTUM 
Working Group. Estimates of cancer burden in Italy. Tu-
mori 2013;99(3):416-24.
8. Cassetti T, la Rosa F, Rossi L, D’Alò D, Stracci F. Cancer 
incidence in men: a cluster analysis of spatial patterns. 
BMC Cancer 2008;8:344.
9. Minelli L, Stracci F, Prandini S, Fusco Moffa I, La Rosa 
F. Gynaecological cancers in Umbria Italy: trends of inci-
dence, mortality and survival, 1978-1998. Eur J Obst Gy-
necol Rep Biol 2004;115:59. 
10. Stracci F, La Rosa F, Falsettini E, Ricci E, Aristei C, 
Bellezza G, Bolis GB, Fenocchio D, Gori S, Rulli A, 
Mastrandrea V. A population survival model for breast 
cancer. Breast 2005;14:94. 
11. La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epide-
miology of prostate cancer in the Umbria region of It-
aly: evidence of opportunistic screening effects. Urology 
2003;62:1040. 
12. RTUP Working Group. Trend temporali di mortalità in Um-
bria 1994-2008. Perugia: Regione dell’Umbria; 2009. 
13. La Rosa F, Canosa A, Petrinelli AM, Stracci F, Cassetti 
T. La mortalità per cause in Umbria. 1994-2004. Perugia: 
Regione dell’Umbria; 2005. 
14. Joinpoint Regression Program, version 4.1.1.1. Surveil-
lance Research. National Cancer Institute, Bethesda, 
Giuseppe Michele Masanotti, Francesca Cioccoloni, Fabrizio Stracci et al.
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
216
USA; updated October 7, 2014. Available from: http://
surveillance.cancer.gov/joinpoint/.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, For-
man D. Global cancer statistics. CA: A Cancer J Clinic 
2011;61:69-90. 
16. Kanavos P. The rising burden of cancer in the developing 
world. Ann Oncol 17(Suppl. 8):viii15-23, 2006.
17. Gatta G, Rossi S, Capocaccia R. Cancer burden estimates 
and forecasts: uses and cautions. Tumori 2013;99(3):439-
43.
18. Schottenfeld D, Fraumeni JF. Cancer Epidemiology and 
Prevention. Oxford University Press, New York: 2006.
19. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri 
E, La Vecchia C. Cancer mortality in the European 
Union, 1970-2003, with a joinpoint analysis. Ann Oncol 
2008;19(4):631-40.
20. Lee YC, Marron M, Benhamou S, Bouchardy C, Ahrens 
W, et al. Active and involuntary tobacco smoking and 
upper aerodigestive tract cancer risks in a multicenter 
case-control study. Cancer Epidemiol Biomark Prev 
2009;18(12):3353-61. 
21. Shih-An L. A Literature Analysis of the Risk Factors for 
Oral Cancer. Oral Cancer 2012;4:73-4.
22. Marron M, Boffetta P, Zhang ZF, et al. Cessation of al-
cohol drinking, tobacco smoking and the reversal of head 
and neck cancer risk. Int J Epidemiol 2010;39(1):182-96.
23. Palli D, Russo A, Decarli A. Dietary patterns, nutrient in-
take and gastric cancer in a high-risk area of Italy. Cancer 
Causes Control 2001;12:163-72.
24. Stracci F, Gruppo di lavoro RTUP. Il quadro epidemio-
logico per la programmazione della prevenzione onco-
logica regionale in Umbria. Cancerstat 2010.
25. Gruppo RTUP. L’incidenza del cancro in Umbria 2006-
2008. Cancerstat 2010. 
26. Stracci F, Petrucci MS, Ciampichini R, Tavilla A, Fos-
chi R. Estimates of cancer burden in Umbria. Tumori 
2013;99(3):342-50.
27. Ribes J, Clèries R, Esteban L, Moreno V, et al. The in-
fluence of alcohol consumption and hepatitis B and C 
infections on the risk of liver cancer in Europe. J Hepatol 
2008;49:233-42.
28. Bosetti C, Bianchi C, Negri E, Colombo M, La Vecchia 
C. Trends in mortality from primary liver cancer in Eu-
rope. Europ J Cancer 2000;36:909-15.
29. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli 
F, Benucci C, Nostro AL. Impact of universal vaccination 
programmes on the epidemiology of hepatitis B: 10 years 
of experience in Italy. Vaccine 2003;21(7-8):685-91. 
30. Bray FI, Weiderpass E. Lung cancer mortality trends 
in 36 European countries: secular trends and birth co-
hort patterns by sex and region 1970-2007. Int J Cancer 
2010;126:1454-66.
31. Jemal A, Thun MJ, Ries LA, et al. Annual report to the 
nation on the status of cancer, 1975-2005, featuring 
trends in lung cancer, tobacco use, and tobacco control. J 
Natl Cancer Inst 2008;100:1672-94.
32. Inghelmann R, Grande E, Francisci S, et al. Regional esti-
mates of lung cancer burden in Italy. Tumori 2007;93:360-
6.
33. Italia. Regione Umbria. Piano Sanitario Regionale 2009-
2011. Deliberazione del Consiglio Regionale 28 aprile 2009. 
Regione Umbria: Perugia, 2009.
34. Crocetti E, Buzzoni C, Falcini F, Cortesi L, De Lisi V, 
Ferretti S, Tumino R, Russo A, Paci E. Disentangling 
the roles of mammographic screening and HRT in recent 
breast cancer incidence trends in Italy by analyses based 
on calendar time and time since screening activation. 
Breast J 2010;16(4):350-5. 
35. Héry C, Ferlay J, Boniol M, Autier P. Changes in breast 
cancer incidence and mortality in middle-aged and elder-
ly women in 28 countries with Caucasian majority popu-
lations. Ann Oncol 2008;19:1009-18.
36. Fontenoy AM, Leux C, Delacour-Billon S, Allioux C, Fre-
nel JS, Campone M, Molinié F. Recent trends in breast 
cancer incidence rates in the Loire-Atlantique, France: a 
decline since 2003. Cancer Epidemiol 2010;34(3):238-43. 
37. Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op 
de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh 
JW, Van Leeuwen FE, Buntinx F. Reduction in hormone 
replacement therapy use and declining breast cancer inci-
dence in the Belgian province of Limburg. Breast Cancer 
Res Treat 2009;118(2):425-32. 
38. Katalinic A, Rawal R. Decline in breast cancer incidence 
after decrease in utilisation of hormone replacement ther-
apy. Breast Cancer Res Treat 2008;107:427-30.
39. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. 
Trends of cervical cancer mortality in the member states 
of the European Union. Eur J Cancer 2009;45(15):2640-8. 
40. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvin-
en A. Prostate cancer incidence and mortality trends 
in 37 European countries: An overview. Eur J Cancer 
2010;46(17):3040-52.
41. World Health Organization, International Agency for Re-
search on Cancer. Exposure to artificial uv radiation and 
skin cancer. Lyon: IARC; 2005. 
42. Breitbart EW, Waldmann A, Nolte S, Capellaro M, 
Greinert R, Volkmer B, Katalinic A. Systematic skin can-
cer screening in Northern Germany. J Am Acad Dermatol 
2012;66(2):201-11.
43. Green A, Williams GM, Logan V, Strutton GM. Reduced 
melanoma after regular sunscreen use: randomized trial 
follow-up. J Clin Oncol 2011;20-29(3):257-63.
44. Gyorya F, Balazsa Gy, Nagyb EV, Juhasza F, Mezo-
sib E, Szakallc Sz, Mathd J, Lukacsa G. Differentiated 
thyroid cancer and outcome in iodine deficiency. EJSO 
2004;30:325-31.
45. Williams D. Radiation carcinogenesis: lessons from Cher-
nobyl. Oncogene 2009;27:S9-18.
46. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjo-
din A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, 
Zhang Y. International patterns and trends in thyroid 
cancer incidence, 1973-2002. Cancer Causes Control 
2009;20(5):525-31.
47. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee 
SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, 
Tuttle RM; American Thyroid Association. Guidelines 
Taskforce. Management guidelines for patients with thy-
roid nodules and differentiated thyroid cancer. Thyroid 
2006;16:109-42.
48. Sipos JA, Mazzaferri EL. Thyroid Cancer Epidemiology 
and Prognostic Variables. Clin Oncol (R Coll Radiol). 
2010;22(6):395-404. 
49. Weny j. Mack, Susan Preston-Martin, Leslie Bernstein, 
Dajun Qian. Lifestyle and Other Risk Factors for Thyroid 
Cancer in Los Angeles County Females. Ann Epidemiol 
2002;12:395-401.
50. World Health Organization. World Health Statistics 2012. 
WHO: France; 2012. 
51. World Health Organization. The world health report 2000 
− Health systems: improving performance. Geneva: WHO; 
2000.
52. Regional Office for Europe. European health for all data-
base. WHO: Copenhagen; 2005.
53. World Health Organization. Research for universal health 
coverage, World Health Report 2013. WHO: Luxembourg; 
2013. 
